Active Recombinant Human ERBB3(Met1-Thr643), mFc-tagged

• Cat.No.: ERBB3-43H
• Product Overview: Active Recombinant Human ERBB3(Met1-Thr643)(P21860), fused with C-terminal mFc tag, was expressed in HEK293.

Specification

• Source: HEK293
• Species: Human
• Tag: mFc
• Protein length: Ser20-Thr643
• Form: Lyophilized from sterile PBS, pH 7.4.
• Bio-activity: Measured by its binding ability in a functional ELISA. Immobilized human ErbB3-mFc at 10 μg/ml (100 μl/well) can bind biotinylated human NRG1, The EC50 of biotinylated human NRG1 is 0.58-1.25 μg/ml.
• Molecular Mass: The recombinant human ErbB3/mFc is a disulfide-linked homodimer. The reduced monomer comprises 858 amino acids and has a predicted molecular mass of 95 kDa. The apparent molecular mass of the protein is approximately 119-129 in SDS-PAGE under reducing conditions.
• Endotoxin: < 1.0 EU per μg of the protein as determined by the LAL method
• Purity: > 95 % as determined by SDS-PAGE.
• Storage: Samples are stable for up to twelve months from date of receipt at -20°C to -80°C. Store it under sterile conditions at -20°C to -80°C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
• Reconstitution: It is recommended that sterile water be added to the vial to prepare a stock solution of 0.2 ug/ul. Centrifuge the vial at 4°C before opening to recover the entire contents.

Gene Information

• Gene Name: ERBB3 v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (avian) [ Homo sapiens ]
• Official Symbol: ERBB3
• Synonyms: ERBB3; v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (avian); LCCS2, lethal congenital contracture syndrome 2; receptor tyrosine-protein kinase erbB-3; HER3; proto-oncogene-like protein c-ErbB-3; tyrosine kinase-type cell surface receptor HER3; LCCS2; ErbB-3; c-erbB3; erbB3-S; MDA-BF-1; c-erbB-3; p180-ErbB3; p45-sErbB3; p85-sErbB3; MGC88033
• Gene ID: 2065
• mRNA Refseq: NM_001005915
• Protein Refseq: NP_001005915
• MIM: 190151
• UniProt ID: P21860

Reviews

10/28/2021

Their expert team has been instrumental in addressing any challenges or concerns I have encountered during my experiments.

08/11/2021

Their prompt and comprehensive assistance has proven invaluable in overcoming obstacles and optimizing my experimental protocols.

03/03/2020

The ERBB3 protein boasts remarkable stability, allowing for extended storage without compromising its integrity or performance.

Q&As

What are the potential side effects of targeting ERBB3 in cancer therapy?

Potential side effects may include skin rash, diarrhea, and cardiovascular issues, as seen with other drugs targeting the EGFR family.

How does ERBB3 contribute to resistance to certain cancer therapies?

ERBB3 activation has been associated with resistance to some targeted therapies, such as EGFR inhibitors, making it a challenging target in cancer treatment.

How does ERBB3 interact with other receptors in the EGFR family?

ERBB3 can form heterodimers with other EGFR family members, such as EGFR and HER2, leading to the activation of downstream signaling pathways.

Can ERBB3 be used as a biomarker for prognosis in cancer patients?

Yes, elevated ERBB3 expression has been linked to poor prognosis in certain cancers, serving as a potential biomarker for patient outcomes.

In which types of cancers is ERBB3 commonly overexpressed?

ERBB3 overexpression is frequently observed in breast, ovarian, and gastric cancers, among others.